



## Evaluation of differing interventions (including pork plasma) at the onset of neonatal calf diarrhea.

D. Wood<sup>1</sup>, R. Blome<sup>1</sup>, A. Keunen<sup>2</sup>, B. Keunen<sup>2</sup>, L. Ribeiro<sup>1</sup>, and D. Renaud<sup>3</sup>. Animix<sup>1</sup>, Juneau, WI, Mapleview Agri Ltd.<sup>2</sup>, Palmerston, ON, Population Medicine, University of Guelph<sup>3</sup>, Guelph, ON.

### Introduction


Spray dried colostrum has shown merit during enteric disease challenge (Berge, et. al.). Spray dried pork plasma is shown to reduce disease symptoms when calves are challenged with *E. coli* (Nollet, et. al). No studies have compared both of these functional protein sources to a common antibiotic regimen to treat diarrhea in young calves.

### Objective

The objective of this study was to investigate strategies to treat diarrhea.

### Material and Methods

Male calves (n=160) sourced from farms and auctions (BW=51.7 ±4.3 kg) were randomly assigned to receive one of 4 treatment regimens commencing at the on-set of a fecal score of 3 or two consecutive fecal scores of 2 (Renaud, 2020), either:



Images: courtesy of Veal Farmers of Ontario

- ⇒ The respective functional protein source was formulated into the 26:20 calf milk replacer (CMR) at the expense of milk protein.
- ⇒ Respective treatment was administered as a substitute for 1 L of milk replacer for 10 consecutive feedings (5 days) after enrollment in the study.
- ⇒ If a calf refused his liter of test diet it was tubed, however, if a calf refused his additional feeding of

the standard CMR it was recorded as a feed refusal.

- ⇒ All milk replacer (including test diets) were administered at 130 g solids/L.

CMR was fed 2x/d in a step-up, step-down fashion (37.8 kg over 56 d) starting at 5 L/d for the first 2 weeks. Texturized starter (20% CP, 4% straw) was offered ad lib. Calves were housed individually in a mechanically ventilated grain-fed veal facility in Ontario.

Measures:

- ⇒ Serum total protein at arrival (refractometer)
- ⇒ Medical treatments, mortality, milk refusals
- ⇒ Individual body weight weekly
- ⇒ Individual fecal score 2x/d (Renaud, 2020)
- ⇒ Individual respiratory score 2x/d (Love, 2014)

Statistical analysis:

- ⇒ Conducted in Stata 17 (StataCorp, TX)
- ⇒ Cox proportion hazard model used to measure mortality and morbidity
- ⇒ Linear regression model to evaluate ADG
- ⇒ Generalized linear model to evaluate fecal and respiratory scores

### Results & Conclusion

Of the 160 calves placed, 59.4% experienced sufficient diarrhea symptoms to enter the study. No differences were found between treatment groups with regard to source ( $P=0.51$ ), crossbred calves (n=20;  $P=0.90$ , the balance were Holstein), serum total protein ( $P=0.60$ ), or incidence of failed transfer of passive immunity (33% of all calves;  $P=0.65$ ). Using a log-rank test of survivor function there was no differences in mortality ( $P=0.73$ ).


### Conclusions:

- No statistical differences in treatment for diarrhea and respiratory disease, mortality, or resolution of diarrhea
- Calves in the antimicrobial group had a greater ADG over the 56 d experimental period. However, no differences were noted in ADG over the first 28 d.
- At d 56, calves in the antimicrobial group weighed more than the control calves, whereas the colostrum and porcine plasma groups tended to weigh more at 56 d
- Approximate cash outlay (US\$): 300 g Saskatoon Colostrum Powder \$22.40, 300 g APC Nutrapro P plasma \$1.65; 15 ml Borgal® trimethoprim sulphadoxine \$1.12. Additional protein value 159 and 234 g from colostrum and plasma respectively. Colostrum also provides 63 g of fat.

### Possible follow-up studies:

- Supplement functional protein prior to diarrhea event
- Increase functional protein dose

**Figure 1.** Predicted median, 25<sup>th</sup> and 75<sup>th</sup> percentile and range of average daily gain over the 56 d experimental period as determined using a linear regression model



	COL	PP	AB	CON
Number (n) of calves enrolled	24	26	22	23
Enrollment (diarrhea onset) growth day	4.2	3.9	4.3	4.3
Mortality (n)	5	3	5	4
Arrival Serum Total Protein (g/dL)	5.29	5.48	5.25	5.27
Trimethoprim sulfa (% 1st scour treat)	75.9%	57.7%	100%	60.9%
Of diarrhea treated, % 2nd treat	0.0%	0.0%	0.0%	0.0%
% treated for respiratory disease	54.2%	46.2%	59.1%	73.9%
Of Respiratory treated, % 2nd treat.	76.9%	83.3%	83.3%	64.7%
Of Respiratory treated 2x, % 3rd treat	50.0%	60.0%	66.7%	54.6%
Body weight (BW) at enrollment (kg)	52.2	51.5	52.3	51.8
56-d post enrollment BW (kg)	94.6 <sup>x</sup>	94.4 <sup>x</sup>	97.7 <sup>a</sup>	91.9 <sup>v,b</sup>
28-d ADG post enrollment (kg)	0.57 ±0.28	0.58 ±0.20	0.59 ±0.23	0.59 ±0.19
56-d ADG post enrollment (kg)	0.77 <sup>a</sup> ±0.20	0.77 <sup>a</sup> ±0.19	0.82 <sup>b</sup> ±0.18	0.72 <sup>a</sup> ±0.16
<sup>a,b</sup> Means within a row different superscripts differ ( $P \leq 0.05$ )				
<sup>x,y</sup> Means within a row different superscripts differ ( $P \leq 0.10$ )				
Treatment groups in study (130 g/L). Calves were enrolled at barn placement and treatment administered at on-set of diarrhea (2 days fecal score 2 or 1 day fecal score 3):				
COL: CMR formulated to 26% CP & 20% fat with spray dried colostrum (Saskatoon Colostrum Company) included at 23% of formula (30 g/ldg)				
PP: CMR formulated to 26% CP & 20% fat with spray dried porcine plasma (APC, Nutrapro P) included at 23% of the formula (30g/ldg)				
AB: CMR formulated to 26% CP & 20% fat with no functional proteins + intramuscular injection of trimethoprim sulphadoxine (Borgal®) at a dose of 3 mL/45 kg 1x/d for 5 consecutive days				
CON: CMR same as AB treatment group but no injectable antibiotic administered				



## References:

Berge ACB, Besser TE, Moore DA, et al. Evaluation of the effects of oral colostrum supplementation during the first fourteen days on the health and performance of preweaned calves. *J Dairy Sci* 2009; 92:286–95.

Love WJ, Lehenbauer TW, Kass PH, Van Eenennaam AL, and Aly SS. 2014. Development of a novel clinical scoring system for on-farm diagnosis of bovine respiratory disease in pre-weaned dairy calves. *PeerJ* 2:e238. <https://doi.org/10.7717/peerj.238>.

Nollet H, Laevens H, Deprez P, et al. The use of non-immune plasma powder in the prophylaxis of neonatal *Escherichia coli* diarrhea in calves. *Am J Vet Med* 1999;46:185–96. <https://doi.org/10.1046/j.1439-0442.1999.00208.x>

Renaud DL., Buss L, Wilms JN, and Steele MA. 2020. Technical note: Is fecal consistency scoring an accurate measure of fecal dry matter in dairy calves. *J. Dairy Sci.* 103:10709–10714. <https://doi.org/10.3168/jds.2020-18907>.